tiprankstipranks

NeoGenomics price target lowered to $16 from $19 at BofA

BofA analyst Derik de Bruin lowered the firm’s price target on NeoGenomics (NEO) to $16 from $19 and keeps a Neutral rating on the shares. Soft Q4 sales led to a 14% stock pullback, though management is confident this miss is only temporary, particularly given the impact of a softer Pharma budget flush, says BofA, which tweaks estimates after the report.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue